Analysis of proliferation and apoptotic induction by 20 steroid glycosides in 143B osteosarcoma cells *in vitro*

C. I. Delebinski*, S. Georgi†, S. Kleinsimon*, M. Twardziok*, B. Kopp‡, M. F. Melzig† and G. Seifert*

*Department of Paediatric Oncology/Haematology, Otto-Heubner-Centre for Paediatric and Adolescent Medicine (OHC), Charité, Universitätsmedizin Berlin, Berlin, 13353, Germany, †FU Berlin, Institute for Pharmacy, Berlin, 14195, Germany and ‡Department of Pharmacognosy, University of Vienna, Vienna, A-1090, Austria

Received 28 April 2015; revision accepted 4 July 2015

Abstract

Objectives: Osteosarcoma is the most common type of malignant bone tumour in children and adolescents; it has poor prognosis, is highly metastatic and is resistant to current therapeutic approaches. In this study, different herbal extracts used in phytotherapy have been screened after searching innovative natural anti-cancer components.

Materials and methods: Twenty steroid glycosides were examined for accordance to their potential of inhibiting cell proliferation and inducing apoptosis in the osteosarcoma cell line 143B. Cell proliferation was examined using a CASY counter. Effects of cardiac glycosides on induction of apoptosis were evaluated by Annexin V-APC and flow cytometry, caspase activity assay and measurement of mitochondrial membrane potential.

Results: The study revealed that various steroid glycosides suppress cell proliferation in a concentration-dependent manner. Further investigations indicated apoptotic induction by 17 of the 20 tested cardenolides and bufadienolides. Bufadienolide proscillaridin A, arenobufagin, and cardenolides evomonoside, convallatoxin and ouabain showed strongest apoptotic induction, associated with breakdown of mitochondrial membrane potential and activation of caspases -8 and -9. In contrast, the bufadienolide resibufogenin and cardenolide uzarin had no effect on proliferation inhibition,

apoptotic induction or change in mitochondrial membrane potential.

Conclusion: These results indicate that bufadienolides proscillaridin A and arenobufagin and cardenolide evomonoside, or related natural compounds might be promising new starting points for development of novel anti-cancer agents for treatment of osteosarcoma.

Introduction

Osteosarcoma is the most common primary malignant bone tumour, mainly occurring in children and adolescents (1). The most challenging problem facing orthopaedic oncologists is to counter multidrug resistance (MDR) induced by classic chemotherapeutic agents such as methotrexate, adriamycin and cisplatin. In the order of 50% of osteosarcoma cases are resistant to chemotherapy or acquire resistance during treatment (2,3). Thus, there is great need for exploring mechanisms of chemotherapeutic resistance and developing new or additional treatment regimens for chemotherapy-resistant osteosarcoma. Novel strategies in cancer therapy based on steroid glycosides are discussed as possibilities for counteracting multidrug resistance by using cardiac glycosides.

Steroid glycosides have been used in the treatment of congestive heart failure, arrhythmia (4,5) and malignant diseases in the past (6,7). They are a category of compounds isolated from plants or animals (mainly *bufo*) from which their names have originated (8). Chemically, they can be categorized into two groups. On the one hand are the cardenolides, characterized by having an unsaturated butyrolactone ring of five members at C-17, plus C-23 steroids, and on the other hand the bufadienolides, which have a six-membered double unsaturated pyrone ring (9). Both groups are able to

Correspondence: G. Seifert, Department of Paediatric Oncology/Haematology, Charité – Universitätsmedizin Berlin, Otto Heubner Centre for Paediatric and Adolescent Medicine (OHC), Augustenburger Platz 1, 13353 Berlin, Germany. Tel.: +49 30 450 666 087; Fax: +49 30 450 566 946; E-mail: georg.seifert@charite.de

bind to and inhibit the Na^+/K^+ -ATPase pump, which results in activation of different signal cascades involved in the mechanism of proliferation, induction of apoptosis or gene expression (10–15). For example, for 19-hydroxy-2-oxovoruscharine anti-cancer activity in chemosensitive versus MDR, cancer and apoptosis-resistant cells, has been described (16–18).

However, over the few last decades, several studies have demonstrated anti-cancer properties of different steroid glycosides, for example digoxin and ouabain in human breast cancer cell lines (19,20). McConkey *et al.* demonstrated apoptotic induction by steroid glycosides such as oleandrin, ouabain and digoxin in human prostate cancer cell lines *in vitro* (14). Digoxin and digitoxin have already been reported in clinical studies to afford therapeutic effectiveness in breast cancer and prostate cancers and leukaemia (21–23). For ouabain and digoxin, apoptotic induction has been described in human acute T-cell lines (24,25). Lopez-Lazaro *et al.* reported that digitoxin inhibited cell proliferation in cancer cell lines at concentrations commonly found in the plasma of cardiac patients (26). Of the bufadienolides, bufalin and cinobufagin, an anti-proliferative effect and anti-cancer properties in prostate cancer and human hepatocellular carcinoma cells have already been published (27,28).

The aim of this study was to analyse growth inhibitory effect and induction of apoptosis in 20 structurally different steroid glycosides, in the 143B osteosarcoma cell line, hopefully to discover new agents to negotiate a way around multidrug resistance.

Materials and methods

Steroid glycosides

A library of cardioactive steroids was obtained from Prof. Brigitte Kopp (Department of Pharmacognosy, University of Vienna, Austria). Their purities were >95% determined by HPLC/UV analysis. The cardenolides desglucocheirotoxin, strophanolloside, lokundjoxide, convallatoxin and the bufadienolide proscillaridin A as well as the bufadienolide aglycons arenobufagin, resibufogenin, bufarenogin, bovogenin A, gamabufogenin, bufotaline and the cardenolide evomonoside, were isolated from *Convallaria majalis* L. toad venoms and *Urginea* species. Their chemical structures were elucidated by NMR spectroscopy and mass spectrometry (MS) as described in more detail previously (29–35).

Cardenolides digitoxin, gitoxin, lanatosid C, digoxin, ouabain, k-strophanthin and helveticoside were purchased from Sigma-Aldrich (Munich, Germany) and uzarin was provided by ChromaDex (Irvine, CA, USA).

Ouabain, k-strophanthin, uzarin and helveticoside were dissolved in phosphate-buffered saline (PBS, Gibco Life technologies, Darmstadt, Germany) to constitute 5 mM stock solutions, and stored at room temperature. Remaining substances were dissolved in DMSO from Sigma-Aldrich for stock solutions (5 mM). Bufarenogin, uzarin and resibufogenin stock solutions were diluted in PBS to a final concentration of 100 μM , the remaining substances to a 20 μM /PBS working solution, before use. Highest DMSO concentration did not exceed 0.04 % (v/v).

Cell culture

Human 143B and U-2OS osteosarcoma cell lines were obtained from the ATCC (American Type Culture Collection, Rockville, MD, USA). 143B was cultured in RPMI 1640 medium, and U-2OS in McCoy's medium supplemented with 10% heat inactivated foetal calf serum (Biochrom, Berlin, Germany), 100 U/ml penicillin and 100 $\mu\text{g}/\text{ml}$ streptomycin at 37 °C and 5% CO_2 . Both cell lines were transferred to six-well plates at $4 \times 10^5/\text{well}$ 18 h before assay set-up. Cells were treated at indicated concentrations and duration with different cardiac glycosides, and then subjected to analysis. RPMI 1640 and McCoy's medium base and penicillin/streptomycin stock solution were purchased from Gibco, Life Technologies.

Effects of cardiac glycosides on cell viability were measured after 4 h using a Cytotoxicity Detection Kit Plus (Roche, Grenzach-Wyhlen, Germany) that quantifies lactate dehydrogenase (LDH) release, according to the manufacturer's protocol.

Propidium iodide and annexin V binding assay

Cells were incubated for 24 h with described cardiac glycosides and concentrations. After incubation, apoptotic level was analysed as described previously (30). Results were evaluated with FlowJo Software (TreeStar, Ashland, OR, USA).

Analysis of mitochondrial membrane potential ($\Delta\Psi\text{m}$)

Mitochondrial membrane potential was assessed using 5,5,6,6-tetrachloro-1,1,3,3-tetraethylbenzimidazol-carbocyanine iodide (JC-1, Sigma-Aldrich) and flow cytometric analysis, as described previously (36). Cells were analysed after 24 h incubation or depicted time points. Depolarizing carbonyl cyanide 3-chlorophenylhydrazone (CCCP; Sigma-Aldrich) was used as reference, cells being treated with 50 μM CCCP (final concentration) for 30 min.

Measurement of caspase activity

Activity of caspases -8 and -9 was measured by fluorescent caspase staining kit according to the manufacturer's protocol (Promokine, Heidelberg, Germany). For caspase inhibitor assay, cells were pre-incubated with 100 μM z-VAD-fmk for 1 h. After additional incubation with depicted cardiac glycosides for 24 h, induction of apoptosis was determined using annexin V-APC/PI with FACS analyses. DMSO was added to extracts as solvent control.

Statistical analyses

Student's *t*-test was applied to determine differences between glycoside-treated cells and controls and significance level was set at $P \leq 0.05$ for all tests.

Results

Steroid glycosides affected proliferation of 143B cells

Anti-proliferative effect of 20 steroid glycosides (Table 1) was evaluated using the CASY[®] Counter system, after incubation with increasing concentrations of reagents (range 0.05–1 μM) for 24 h. Cell population growth was inhibited in a dose-dependent manner in 17 of the 20 steroid glycoside-treated cells (Fig. 1). Classical digitalis glycosides ouabain and digitoxin, were able to inhibit cell proliferation within a range of 0.1–0.15 μM (50% cell population growth inhibition). Data in Fig. 1 demonstrate that most efficient anti-proliferative effect

was obtained by cardenolides convallatoxol and evomonoside and bufadienolide proscillaridin A, as well as ouabain and bufadienolide aglycon arenobufagin A. In contrast, neither uzarin nor resibufagenin altered cell proliferation after 24 h incubation.

Steroid glycosides induced apoptosis in a concentration-dependent manner

To assess possible effects of steroid glycosides on apoptotic induction, 143B cells were incubated with increasing doses of identical steroid glycosides as used before. Figure 2 displays apoptotic induction after 24 h. Glycosides evomonoside, ouabain and arenobufagenin caused 50% apoptotic induction in a range of 0.05–0.15 μM , whereas bufotalin, bovogenin A, lokundjoside, desglucocheirotoxin and strophanollosid induced 50% apoptosis in a range of 0.2–1 μM . Treatment with bufadienolide proscillaridin A showed strongest apoptotic effect between 0.05 and 0.1 μM .

Steroid glycosides induced apoptosis via the mitochondrial pathway

To determine whether apoptotic induction by the most effective cardiac glycosides (IC50 range between 0.05 and 0.2 μM) was attributable to breakdown of mitochondrial membrane potential ($\Delta\Psi\text{m/MMP}$), cells were incubated under the same conditions as before and analysed after JC-1 staining, by flow cytometry. Data in Fig. 3 reveal dose-dependent breakdown of $\Delta\Psi\text{m}$ for all tested substances.

Table 1. Overview of used cardiac glycosides

Drug	Originated from	Family
Convallatoxol	<i>Convallaria majalis</i> L.	Cardenolide glycoside
Desglucocheirotoxin	<i>Convallaria majalis</i> L.	Cardenolide glycoside
Digitoxin	<i>Digitalis purpurea</i> L.	Cardenolide glycoside
Digoxin	<i>Digitalis lanata</i> Ehrh.	Cardenolide glycoside
Evomonoside	<i>Euonymus europaeus</i> L.	Cardenolide glycoside
Gitoxin	<i>Digitalis purpurea</i> L.	Cardenolide glycoside
Helveticoside	<i>Erysimum cheiranthoides</i> L.	Cardenolide glycoside
k-strophanthin	<i>Strophanthus kombé</i> Oliv.	Cardenolide glycoside
Lanatosid C	<i>Digitalis lanata</i> Ehrh.	Cardenolide glycoside
Lokundjoside	<i>Convallaria majalis</i> L.	Cardenolide glycoside
Strophanollosid	<i>Convallaria majalis</i> L.	Cardenolide glycoside
Uzarin	<i>Xysmalobium undulatum</i> (L.) R.Br.	Cardenolide glycoside
Ouabain	<i>Strophanthus gratus</i> (Wall. et Hook. Ex Benth.) Baill.	Cardenolide glycoside
Proscillaridin A	<i>Drimia maritima</i> (L.) Stearn	Bufadienolide glycoside
Arenobufagin	<i>Bufo melanostictus</i> Schneider, 1799	Bufadienolide aglycon
Bovogenin A	<i>Bufo melanostictus</i> Schneider, 1799	Bufadienolide aglycon
Bufarenogin	<i>Bufo melanostictus</i> Schneider, 1799	Bufadienolide aglycon
Bufotaline	<i>Bufo melanostictus</i> Schneider, 1799	Bufadienolide aglycon
Gamabufotalin	<i>Bufo melanostictus</i> Schneider, 1799	Bufadienolide aglycon
Resibufogenin	<i>Bufo melanostictus</i> Schneider, 1799	Bufadienolide aglycon

Figure 1. Inhibition of cell population growth of steroid glycoside-treated cells. 143B cells were treated with a range of steroid glycoside concentrations (0.05–10 μM) for 24 h. Cell counts were analysed *via* CASY® Counter. Eighteen of 20 steroid glycosides were able to inhibit cell proliferation in a concentration-dependent manner ($n = 3$).

Time-dependent analysis of apoptotic induction by the most potent substances, evomonoside, proscillaridin A and arenobufagin

Next, level of apoptosis and breakdown of MMP were analysed at different time points for the three most effective glycosides (proscillaridin A, arenobufagin, evomonoside). Data in Fig. 4 reveal that drug-induced apoptosis occurred after 6 h and that there was no significant difference in apoptotic level and loss of mitochondrial membrane potential between 16 and 24 h. To exclude unwanted cytotoxic effects such as necrosis, LDH release was measured after 4 h incubation with proscillaridin A, arenobufagin and evomonoside. As shown in Fig. 4b, no significant LDH release was measurable for different doses of the three tested drugs.

Furthermore, effectiveness of proscillaridin, evomonoside and arenobufagin was analysed in a secondary osteosarcoma cell line U-2OS. In that, these glycosides were also able to induce apoptosis in a

concentration-dependent manner accompanied by loss of $\Delta\Psi\text{m}$ (Fig. S1), but were less sensitive to the glycosides than line 143B.

Cardiac glycosides affected caspase activity of both intrinsic and extrinsic apoptotic pathways

For further characterization of the molecular pathways involved in apoptosis, activation of caspases -8 and -9 were assessed in 143B cells. Both caspases are upstream initiator proteases, which play key roles in the extrinsic (caspase-8) or the intrinsic (caspase-9) apoptotic pathway. Data in Fig. 5a reveal similar activation of both caspases by proscillaridin, evomonoside and arenobufagin in a concentration-dependent manner.

To analyse the role of caspases, 143B cells were treated in the absence or presence of the broad range caspase inhibitor z-VAD-fmk. In all three treated cell types, z-VAD-fmk treatment reduced apoptotic induction between 30% and 40%.

Figure 2. Apoptotic induction in 143B cells by steroid glycosides. Cells were incubated with depicted concentrations of steroid glycosides for 24 h. After treatment, induction of apoptosis was analysed using annexin V-APC and propidium iodide (PI). Values are given as percentages of annexin-positive cells $\pm$ SD. Seventeen of the 20 cardiac glycosides increased percentages of annexin V-positive cells in a dose-dependent manner ($n = 3$). Asterisk represents statistically significant differences compared to control group (* $P < 0.05$, ** $P < 0.001$).

Figure 3. Steroid glycosides induced mitochondrial membrane depolarization. Cells were treated with the most effective steroid glycosides for 24 h and mitochondrial membrane potential was evaluated using fluorescent dye JC-1 and flow cytometry. Values of mitochondrial permeability transition are given as percentages of cells with low MMP $\pm$ SD ($n = 3$). Asterisk represents statistically significant differences compared to control group (* $P < 0.05$).

These results indicate that both extrinsic and intrinsic signalling pathways play a role in cardiac glycoside-induced apoptosis in osteosarcoma *in vitro*.

Discussion

Previous studies have shown anti-proliferative and anti-tumour properties for some analysed steroid glycosides

in various cancer cell lines, although little has been known concerning their effects on osteosarcoma cells. To our knowledge, this is the first time that an anti-proliferative effect and apoptotic induction have been analysed for evomonoside, convallatoxin, lokundjoxide, desglucocheirotxin and strophanolloside in cancer cells. These five cardenolides have the ability to inhibit cell proliferation and exert induction of apoptosis in a

Figure 4. Apoptotic induction took place after 6 h incubation. Cells were incubated with described concentrations of proscillaridin A, evomonoside and arenobufagin for 6, 16 or 24 h. After incubation, apoptotic level and loss of mitochondrial membrane potential were analysed as shown previously. Early cytotoxicity was measured after 4 h incubation, by LDH release assay. There was no relevant induction of LDH release after 4 h by the three steroid glycosides. ($n = 3$). Asterisk represents statistically significant differences compared to control group (* $P < 0.05$, ** $P < 0.001$).

concentration range in the order of 0.080–1 μM . Here, evomonoside had the strongest effect within 0.08–0.15 μM . In the literature, we found no data to be available on an anti-cancer effect of this cardenolide.

By comparison of all 20 steroid glycosides analysed here, the bufadienolide proscillaridin A displayed the strongest effect in causing apoptosis and inhibition of cell proliferation. Johansson *et al.* have shown apoptotic induction in 9 of 10 analysed human cancer cell lines at concentration of 0.06–0.67 μM (37). In our study, concentration ranged between 0.05 and 0.1 μM . Bielawski *et al.* demonstrated an anti-proliferative effects of proscillaridin A, digitoxin and ouabain at nanomolar drug concentrations, whereas proscillaridin A was much more effective at lower concentrations (0.03 μM for

proscillaridin A, 0.1 μM for digitoxin and ouabain) in breast cancer cells (38). In glioblastoma, proscillaridin A causes cytotoxicity *in vitro* (IC₅₀ 2–4 nM), reduces tumour weight and improves survival of tumour bearing mice *in vivo* (39). Recent studies by Cerella *et al.* have validated Mcl-1 as a common target of cardenolides (40), with down-regulation of Mcl-1 before apoptotic induction in U937 cells, not only for the hemi-synthetic cardenolide UNBS1450 but also for proscillaridin, ouabain, digoxin and digitoxin. These data are consistent with the results obtained by other groups at the level of protein expression under requirement of proteasome degradation (41,42).

Anti-proliferative effects of 27 bufadienolides have been reported in six human and two mouse cancer cell

Figure 5. Activation of caspases -8 and -9 in glycoside-induced apoptosis. (a) Cells were treated with depicted glycosides and activity of caspases -8 and -9 were analysed by FITC-LEHD and FITC-IETD and flow cytometry after 24 h; $\pm$ SD, $n = 3$. (b) Cells were treated with proscillaridin, evomonoside or arenobufagin for 24 h in the presence or absence of 100 μ M Z-VAD-fmk. Effects of caspase inhibitor were analysed using annexin V/propidium iodide staining and flow cytometry, $\pm$ SD, $n = 3$. Asterisk represents statistically significant differences compared to control group ($*P < 0.05$).

lines in comparison to ouabain and digoxin. Moreno *et al.* showed that several bufadienolides, for example gamabufotalin rhamnoside (2–8 nM), bufotalin (9–74 nM) and hellebrin (7–68 nM), displayed higher rates of proliferation inhibition than digoxin (40–266 nM) and ouabain (28–211 nM) after 3 days culture (32).

In our study, strongest effect in cell population growth inhibition and apoptotic induction among the group of cardiac glycosides, was observed for the common cardiac glycosides ouabain > digitoxin > digoxin > k-strophantoin. For these glycosides, apoptotic level has been shown *in vitro* and *in vivo* (43,44).

For the cardiotonic steroid ouabain, an anti-proliferative effect was observed, at the very high concentrations of 1–10 μ M, in three different prostate and breast cancer and leukaemia cell lines (20,45). Moreover, activity of caspases -3 and -9 was described in HeLa, neuroblastoma SH-SY5Y and human fibroblasts (46). Furthermore, ouabain triggered cytochrome c release from mitochondria in neuroblastoma and HeLa cells in correlation with down-regulation of anti-apoptotic proteins Bcl-2 and Bcl-XL (43,46). Recent studies have proposed caspase-independent autophagic cell death *via* JNK activation and Bcl-2 reduction, for ouabain, in non-small cell

lung cancer (concentration 50–100 nM) (44). Pezzani *et al.* were able to show an anti-proliferative effect in adrenocortical cell lines, whereas concentrations from 1 to 1000 nM did not induce apoptosis after 24 h (47). In our study, we observed both inhibition of cell population growth and induction of apoptosis, at clearly lower concentrations than described previously. Overall, these data indicate that the ouabain-induced apoptotic mechanism might be dependent on the particular cancer under consideration. Hiyoshi *et al.* have reported that ouabain significantly reduced tumour growth in a xenografted neuroblastoma mouse model *in vivo* without significant toxicity to the host (48). These data were confirmed by two other groups with an AML and prostate cancer xenograft mouse models (49,50).

For digitoxin, Stenkvist *et al.* reported epidemiological studies in which women with breast cancer on digitalis therapy developed more benign forms of breast tumour and succumbed to levels death (6%) compared to control patients (51–53). Furthermore, the recurrence rate of patients with digitalis treatment was 9.6-times lower than that of control patients.

Within the group of bufadienolide aglycons in our study, arenobufagin A was the most effective glycoside. Effectiveness of bufadienolide aglycons in order of

rank are: arenobufagin A > gamabufotalin > bufotalin > bovogenin A. Arenobufagin A is listed as a key cardiotonic steroid of toad venom, but only a small number of studies on arenobufagin and cancer, seem to have been published. We observed induction of apoptosis, accompanied by loss of mitochondrial membrane potential and activation of caspases -8 and -9, between 0.1 and 0.2 μM of arenobufagin A. Additionally, arenobufagin A markedly inhibited population growth of 143B cells. In accord with our results, Zhang *et al.* reported for the first time that arenobufagin A induced apoptosis *via* caspase 3- and -9 activation and autophagy through inhibition of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway in hepatocellular carcinoma (HCC) cells, in a concentration range between 0.2 and 0.5 μM (54). Moreover it has been reported that arenobufagin is able to block the Na^+/K^+ -ATPase pump (55) and vascular endothelial growth factor-mediated angiogenesis, in several human cancer cell lines, *in vitro* and *in vivo* (56).

The bufadienolide bufalin was the first identified bufadienolide to be analysed as a potential agent in different osteosarcoma cell lines *in vitro* and *in vivo* (57–62). Xie *et al.* demonstrated strong inhibition of tumour growth in a methotrexate-resistant cancer model *in vivo*, without reduction in host body weight (63). Other studies have shown caspase-independent apoptotic induction with involvement of autophagy-mediated cell death and JNK activation, after bufalin treatment (64,65).

Mechanisms of cardiac glycoside activity in cardiac disease treatment, with involvement of Na^+/K^+ -ATPase are well characterized, whereas less is known regarding mechanisms of their anti-cancer effects. Correlation between binding to Na^+/K^+ -ATPase and apoptotic induction plays an important role in the question of anti-cancer mechanisms. Binding to Na^+/K^+ -ATPase leads to inhibition of ATPase, increase in intracellular Na^+ and Ca^{2+} , intracellular reduction in K^+ and inhibition of IL-8 production and the TNF- α /NF- κB pathway. Furthermore, DNA topoisomerase II was found to have been inhibited and the Src kinase pathway was activated (10,11,66,67). For digitoxin, it has already been described that apoptotic induction is connected to inhibition of Na^+/K^+ -ATPase and increase in intracellular Ca^{2+} (14,68). For human lung adenocarcinoma, anti-cancer effects of ouabain have been reported to regulate and inactivate Src-to-ezrin signalling, Na^+/K^+ -ATPase subunits and proteins involved in focal adhesion (69). However, Akimova *et al.* reported that ouabain and other cardiac glycosides induced apoptosis in vascular endothelial cells and renal epithelial cells, Na^+/K^+ independently (70,71). One explanation for the different potency of apoptotic induction by the investigated steroidal glycosides could be different

affinity to a Na^+/K^+ -ATPase α -subunit, which is not primarily involved in ion efflux but in signal transduction, within the process of apoptotic induction (72). Further studies are warranted to examine whether inhibition of Na^+/K^+ -ATPase is the main target structure for induction of apoptosis.

Moreover, several cardiac glycosides are known to be potent P-glycoprotein inhibitors with low resistance indices in multidrug resistant P-glycoprotein-overexpressing cells (37,73,74). Overexpression of the ABC transporter P-glycoprotein is responsible for classical MDR, by extruding chemotherapeutics to the outside of the cell. Thus, cardiac glycosides with the capability of modulating P-glycoprotein, represent a significant source of alternatives in cancer treatment. Mahringer *et al.* analysed the potential of P-glycoprotein inhibition by 57 compounds used in Chinese medicine combined with inhibition of cancer cell population growth. Among these, bufalin was identified as a potent inhibitor without any cross-resistance, whereas proscillaridin inhibited P-glycoprotein with low cross-resistance. Resibufogenin interestingly revealed collateral sensitivity in drug resistant CEM/ADR5000 cells (74). In that study, microRNA expression experimentation revealed an MDR-independent cytotoxic effect for the analysed bufadienolides, except for resibufogenin.

Some theories on the mechanism of inhibition are mentioned below. On the one hand cardiac glycosides can act as transport-independent inhibitors of P-glycoprotein-like cyclosporine A. On the other hand, it has been shown that they are able to inhibit stimulated P-glycoprotein ATPase activity slightly, despite acting as substrates for P-glycoprotein (73). To gain more insight into the details of the mechanisms and the role of P-glycoprotein for our compounds, further studies need to be performed.

The results from the *in vivo* studies of, for example ouabain and bufalin, and clinical trials with digitoxin and digoxin, support the idea that therapeutic potential of these drugs should be further evaluated in cancer patients. To counteract chemotherapeutic resistance, a combination of polychemotherapy with novel strategies is indispensable for osteosarcoma therapy. In our study, we provide a first hint for cardiac glycosides as anti-cancer drugs for osteosarcoma treatment. We have been able to show cell population growth inhibition, not only for common cardiac glycosides like ouabain, digoxin and digitoxin, but also for proscillaridin A, evomonoside and arenobufagin A. Our findings suggest that these cardiac glycosides are promising candidates for combined therapy with classical chemotherapeutic agents, to achieve potential synergism of effectiveness in treatment, and to overcome resistance to apoptosis in

patients currently with dismal prognoses. Thus, the therapeutic potential of steroid glycosides in combination with cytostatics must be further evaluated *in vivo*.

References

- Mirabello L, Troisi RJ, Savage SA (2009) Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. *Cancer* **115**, 1531–1543.
- Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC *et al.* (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. *J. Natl Cancer Inst.* **99**, 112–128.
- Ritter J, Bielack SS (2010) Osteosarcoma. *Ann. Oncol.* **21**(Suppl 7), vii320–vii325.
- Krenn L, Kopp B (1998) Bufadienolides from animal and plant sources. *Phytochemistry* **48**, 1–29.
- Bessen HA (1986) Therapeutic and toxic effects of digitalis: William Withering, 1785. *J. Emerg. Med.* **4**, 243–248.
- Newman RA, Yang P, Pawlus AD, Block KI (2008) Cardiac glycosides as novel cancer therapeutic agents. *Mol. Interv.* **8**, 36–49.
- Furstenwerth H (2010) Ouabain – the insulin of the heart. *Int. J. Clin. Pract.* **64**, 1591–1594.
- Prassas I, Diamandis EP (2008) Novel therapeutic applications of cardiac glycosides. *Nat. Rev. Drug Discov.* **7**, 926–935.
- Gao H, Popescu R, Kopp B, Wang Z (2011) Bufadienolides and their antitumor activity. *Nat. Prod. Rep.* **28**, 953–969.
- Yu SP (2003) Na⁺, K⁺-ATPase: the new face of an old player in pathogenesis and apoptotic/hybrid cell death. *Biochem. Pharmacol.* **66**, 1601–1609.
- Yu SP (2003) Regulation and critical role of potassium homeostasis in apoptosis. *Prog. Neurobiol.* **70**, 363–386.
- Panayiotidis MI, Bortner CD, Cidlowski JA (2006) On the mechanism of ionic regulation of apoptosis: would the Na⁺/K⁺ -ATPase please stand up? *Acta Physiol. (Oxf.)* **187**, 205–215.
- Panayiotidis MI, Franco R, Bortner CD, Cidlowski JA (2010) Ouabain-induced perturbations in intracellular ionic homeostasis regulate death receptor-mediated apoptosis. *Apoptosis* **15**, 834–849.
- McConkey DJ, Lin Y, Nutt LK, Ozel HZ, Newman RA (2000) Cardiac glycosides stimulate Ca²⁺ increases and apoptosis in androgen-independent, metastatic human prostate adenocarcinoma cells. *Cancer Res.* **60**, 3807–3812.
- Mijatovic T, Kiss R (2013) Cardiotonic steroids-mediated Na⁺/K⁺ -ATPase targeting could circumvent various chemoresistance pathways. *Planta Med.* **79**, 189–198.
- Lefranc F, Mijatovic T, Kondo Y, Sauvage S, Roland I, Debeir O *et al.* (2008) Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. *Neurosurgery* **62**, 211–221; discussion 221–222.
- Mijatovic T, Roland I, Van Quaquebeke E, Nilsson B, Mathieu A, Van Vynckt F *et al.* (2007) The alpha1 subunit of the sodium pump could represent a novel target to combat non-small cell lung cancers. *J. Pathol.* **212**, 170–179.
- Mijatovic T, Jungwirth U, Heffeter P, Hoda MA, Dornetshuber R *et al.* (2009) The Na⁺/K⁺ -ATPase is the Achilles heel of multi-drug-resistant cancer cells. *Cancer Lett.* **282**, 30–34.
- Winnicka K, Bielawski K, Bielawska A, Mityk W (2007) Apoptosis-mediated cytotoxicity of ouabain, digoxin and proscillaridin A in the estrogen independent MDA-MB-231 breast cancer cells. *Arch. Pharm. Res.* **30**, 1216–1224.
- Winnicka K, Bielawski K, Bielawska A, Surazynski A (2008) Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells. *Biol. Pharm. Bull.* **31**, 1131–1140.
- Platz EA, Yegnasubramanian S, Liu JO, Chong CR, Shim JS, Kenfield SA *et al.* (2011) A novel two-stage, transdisciplinary study identifies digoxin as a possible drug for prostate cancer treatment. *Cancer Discov.* **1**, 68–77.
- Bagrov AY, Shapiro JI, Fedorova OV (2009) Endogenous cardiotonic steroids: physiology, pharmacology, and novel therapeutic targets. *Pharmacol. Rev.* **61**, 9–38.
- Haux J, Klepp O, Spigset O, Tretli S (2001) Digitoxin medication and cancer; case control and internal dose-response studies. *BMC Cancer* **1**, 11.
- Ihenetu K, Qazzaz HM, Crespo F, Fernandez-Botran R, Valdes R Jr (2007) Digoxin-like immunoreactive factors induce apoptosis in human acute T-cell lymphoblastic leukemia. *Clin. Chem.* **53**, 1315–1322.
- Hallbook H, Felth J, Eriksson A, Fryknes M, Bohlin L, Larsson R *et al.* (2011) Ex vivo activity of cardiac glycosides in acute leukaemia. *PLoS ONE* **6**, e15718.
- Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA, Cortes F *et al.* (2005) Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. *J. Nat. Prod.* **68**, 1642–1645.
- Yu CH, Kan SF, Pu HF, Jea Chien E, Wang PS (2008) Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. *Cancer Sci.* **99**, 2467–2476.
- Qi F, Inagaki Y, Gao B, Cui X, Xu H, Kokudo N *et al.* (2011) Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. *Cancer Sci.* **102**, 951–958.
- Gao H, Zehl M, Kaehlig H, Schneider P, Stuppner H, Moreno YBL *et al.* (2010) Rapid structural identification of cytotoxic bufadienolide sulfates in toad venom from *Bufo melanostictus* by LC-DAD-MS(n) and LC-SPE-NMR. *J. Nat. Prod.* **73**, 603–608.
- Gao H, Zehl M, Leitner A, Wu X, Wang Z, Kopp B (2010) Comparison of toad venoms from different *Bufo* species by HPLC and LC-DAD-MS/MS. *J. Ethnopharmacol.* **131**, 368–376.
- Krenn L, Ferth R, Robien W, Kopp B (1991) Bufadienolides from *Urginea maritima* sensu stricto. *Planta Med.* **57**, 560–565.
- Moreno YBL, Urban E, Gelbcke M, Dufrasne F, Kopp B, Kiss R *et al.* (2013) Structure-activity relationship analysis of bufadienolide-induced in vitro growth inhibitory effects on mouse and human cancer cells. *J. Nat. Prod.* **76**, 1078–1084.
- Krenn L, Jambrits M, Kopp B (1988) Bufadienolides from *Urginea hesperia*. *Planta Med.* **54**, 227–232.
- Kopp B, Kubelka W (1982) New cardenolides from *Convallaria majalis*. *Planta Med.* **45**, 195–202.
- Kimura M, Thoma M, Kikuchi T (1962) The constituents of *Convallaria*. II. The isolation of desglucocheirotoxin. *Yakugaku Zasshi* **82**, 1320–1323.
- Delebinski CI, Jaeger S, Kemnitz-Hassanin K, Henze G, Lode HN, Seifert GJ (2012) A new development of triterpene acid-containing extracts from *Viscum album* L. displays synergistic induction of apoptosis in acute lymphoblastic leukaemia. *Cell Prolif.* **45**, 176–187.
- Johansson S, Lindholm P, Gullbo J, Larsson R, Bohlin L, Claesson P (2001) Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells. *Anticancer Drugs* **12**, 475–483.
- Bielawski K, Winnicka K, Bielawska A (2006) Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer

- MCF-7 cells by ouabain, digoxin and proscillaridin A. *Biol. Pharm. Bull.* **29**, 1493–1497.
- 39 Denicolai E, Baeza-Kallee N, Tchoghandjian A, Carre M, Colin C *et al.* (2014) Proscillaridin A is cytotoxic for glioblastoma cell lines and controls tumor xenograft growth in vivo. *Oncotarget* **5**, 10934–10948.
 - 40 Cerella C, Muller F, Gaigneaux A, Radogna F, Viry E, Chateauvieux S *et al.* (2015) Early downregulation of Mcl-1 regulates apoptosis triggered by cardiac glycoside UNBS1450. *Cell Death Dis.* **6**, e1782.
 - 41 Chanvorachote P, Pongrakhananon V (2013) Ouabain downregulates Mcl-1 and sensitizes lung cancer cells to TRAIL-induced apoptosis. *Am. J. Physiol. Cell Physiol.* **304**, C263–C272.
 - 42 Pongrakhananon V, Stueckle TA, Wang HY, O'Doherty GA, Dinu CZ, Chanvorachote P *et al.* (2014) Monosaccharide digitoxin derivative sensitize human non-small cell lung cancer cells to anoikis through Mcl-1 proteasomal degradation. *Biochem. Pharmacol.* **88**, 23–35.
 - 43 Ramirez-Ortega M, Maldonado-Lagunas V, Melendez-Zajgla J, Carrillo-Hernandez JF, Pastelin-Hernandez G, Picazo-Picazo O *et al.* (2006) Proliferation and apoptosis of HeLa cells induced by in vitro stimulation with digitalis. *Eur. J. Pharmacol.* **534**, 71–76.
 - 44 Trenti A, Grumati P, Cusinato F, Orso G, Bonaldo P, Trevisi L *et al.* (2014) Cardiac glycoside ouabain induces autophagic cell death in non-small cell lung cancer cells via a JNK-dependent decrease of Bcl-2. *Biochem. Pharmacol.* **89**, 197–209.
 - 45 Yeh JY, Huang WJ, Kan SF, Wang PS (2001) Inhibitory effects of digitalis on the proliferation of androgen dependent and independent prostate cancer cells. *J. Urol.* **166**, 1937–1942.
 - 46 Kulikov A, Eva A, Kirch U, Boldyrev A, Scheiner-Bobis G (2007) Ouabain activates signaling pathways associated with cell death in human neuroblastoma. *Biochim. Biophys. Acta* **1768**, 1691–1702.
 - 47 Pezzani R, Rubin B, Redaelli M, Radu C, Barollo S, Cicala MV *et al.* (2014) The antiproliferative effects of ouabain and everolimus on adrenocortical tumor cells. *Endocr. J.* **61**, 41–53.
 - 48 Hiyoshi H, Abdelhady S, Segerstrom L, Sveinbjornsson B, Nuriya M, Lundgren TK *et al.* (2012) Quiescence and gammaH2AX in neuroblastoma are regulated by ouabain/Na, K-ATPase. *Br. J. Cancer* **106**, 1807–1815.
 - 49 Tailler M, Senovilla L, Lainey E, Thepot S, Metivier D, Sébert M *et al.* (2012) Antineoplastic activity of ouabain and pyrithione zinc in acute myeloid leukemia. *Oncogene* **31**, 3536–3546.
 - 50 Simpson CD, Mawji IA, Anyiwe K, Williams MA, Wang X, Venugopal AL *et al.* (2009) Inhibition of the sodium potassium adenosine triphosphatase pump sensitizes cancer cells to anoikis and prevents distant tumor formation. *Cancer Res.* **69**, 2739–2747.
 - 51 Stenkvist B (1999) Is digitalis a therapy for breast carcinoma? *Oncol. Rep.* **6**, 493–496.
 - 52 Stenkvist B, Bengtsson E, Eklund G, Eriksson O, Holmquist J, Nordin B *et al.* (1980) Evidence of a modifying influence of heart glucosides on the development of breast cancer. *Anal. Quant. Cytol.* **2**, 49–54.
 - 53 Stenkvist B, Bengtsson E, Eriksson O, Holmquist J, Nordin B, Westman-Naeser S (1979) Cardiac glycosides and breast cancer. *Lancet* **1**, 563.
 - 54 Zhang DM, Liu JS, Deng LJ, Chen MF, Yiu A, Cao HH *et al.* (2013) Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway. *Carcinogenesis* **34**, 1331–1342.
 - 55 Cruz Jdos S, Matsuda H (1993) Arenobufagin, a compound in toad venom, blocks Na(+)-K+ pump current in cardiac myocytes. *Eur. J. Pharmacol.* **239**, 223–226.
 - 56 Li M, Wu S, Liu Z, Zhang W, Xu J, Wang Y *et al.* (2012) Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signaling pathway. *Biochem. Pharmacol.* **83**, 1251–1260.
 - 57 Wang J, Yin JQ, Jia Q, Shen JN, Huang G, Xie XB *et al.* (2010) Bufalin induces apoptosis in osteosarcoma U-2OS and U-2OS methotrexate 300-resistant cell lines in vitro. *Zhonghua Zhong Liu Za Zhi* **32**, 734–738.
 - 58 Xie XB, Wen LL, Yin JQ, Liao HY, Zou CY, Wang B *et al.* (2014) Proteomics research of bufalin-induced apoptosis in osteosarcoma cell lines. *Zhongguo Zhong Yao Za Zhi* **39**, 2739–2743.
 - 59 Chang Y, Zhao Y, Zhan H, Wei X, Liu T, Zheng B (2014) Bufalin inhibits the differentiation and proliferation of human osteosarcoma cell line hMG63-derived cancer stem cells. *Tumour Biol.* **35**, 1075–1082.
 - 60 Chueh FS, Chen YY, Huang AC, Ho HC, Liao CL, Yang JS *et al.* (2014) Bufalin-inhibited migration and invasion in human osteosarcoma U-2 OS cells is carried out by suppression of the matrix metalloproteinase-2, ERK, and JNK signaling pathways. *Environ. Toxicol.* **29**, 21–29.
 - 61 Wang D, Bi Z (2014) Bufalin inhibited the growth of human osteosarcoma MG-63 cells via down-regulation of Bcl-2/Bax and triggering of the mitochondrial pathway. *Tumour Biol.* **35**, 4885–4890.
 - 62 Yin JQ, Shen JN, Su WW, Wang J, Huang G, Jin S *et al.* (2007) Bufalin induces apoptosis in human osteosarcoma U-2OS and U-2OS methotrexate300-resistant cell lines. *Acta Pharmacol. Sin.* **28**, 712–720.
 - 63 Xie XB, Yin JQ, Wen LL, Gao ZH, Zou CY, Wang J *et al.* (2012) Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research. *PLoS ONE* **7**, e47375.
 - 64 Xie CM, Chan WY, Yu S, Zhao J, Cheng CH (2011) Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and JNK activation. *Free Radic. Biol. Med.* **51**, 1365–1375.
 - 65 Watabe M, Ito K, Masuda Y, Nakajo S, Nakaya K (1998) Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. *Oncogene* **16**, 779–787.
 - 66 Bortner CD, Cidlowski JA (2014) Ion channels and apoptosis in cancer. *Philos. Trans. R. Soc. Lond. B Biol. Sci.* **369**, 20130104.
 - 67 Bortner CD, Cidlowski JA (2004) The role of apoptotic volume decrease and ionic homeostasis in the activation and repression of apoptosis. *Pflügers Arch.* **448**, 313–318.
 - 68 Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the calcium-apoptosis link. *Nat. Rev. Mol. Cell Biol.* **4**, 552–565.
 - 69 Shin HK, Ryu BJ, Choi SW, Kim SH, Lee K (2015) Inactivation of Src-to-ezrin pathway: a possible mechanism in the ouabain-mediated inhibition of A549 cell migration. *Biomed. Res. Int.* **2015**, 537136.
 - 70 Akimova OA, Lopina OD, Rubtsov AM, Gekle M, Tremblay J, Hamet P *et al.* (2009) Death of ouabain-treated renal epithelial cells: evidence for p38 MAPK-mediated Na (i) (+)/K (i) (+)-independent signaling. *Apoptosis* **14**, 1266–1273.
 - 71 Akimova OA, Lopina OD, Rubtsov AM, Hamet P, Orlov SN (2010) Investigation of mechanism of p38 MAPK activation in renal epithelial cell from distal tubules triggered by cardiotonic steroids. *Biochemistry (Mosc)* **75**, 971–978.
 - 72 Chan SH, Leu WJ, Hsu LC, Chang HS, Hwang TL, Chen IS *et al.* (2013) Reevesioside F induces potent and efficient anti-proliferative and apoptotic activities through Na(+)/K(+)-ATPase alpha3 sub-

unit-involved mitochondrial stress and amplification of caspase cascades. *Biochem. Pharmacol.* **86**, 1564–1575.

- 73 Zeino M, Paulsen MS, Zehl M, Urban E, Kopp B, Efferth T (2015) Identification of new P-glycoprotein inhibitors derived from cardiotonic steroids. *Biochem. Pharmacol.* **93**, 11–24.
- 74 Mahringer A, Karamustafa S, Klotz D, Kahl S, Konkimalla VB, Wang Y (2010) Inhibition of P-glycoprotein at the blood-brain barrier by phytochemicals derived from traditional Chinese medicine. *Cancer Genomics Proteomics* **7**, 191–205.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Fig. S1 Apoptotic induction in U2OS cells. A. U2OS were incubated with depicted concentrations of steroid glycosides for 24 h. After treatment, apoptotic induction was analysed with annexin V-APC and propidium iodide (PI). Values are given as percentages of annexin-positive cells $\pm$ SD. B. Mitochondrial membrane potential was evaluated using fluorescent dye JC-1 and flow cytometry. Values of mitochondrial permeability transition are given as percentages of cells with low MMP $\pm$ SD ($n = 3$). Asterisk represents statistically significant differences compared to control group (* $P < 0.05$, ** $P < 0.001$).